CALLABLE MULTI DEFENDER VONTI - NOVO-NORDISK B/YPSOMED N | Market Closed - Swiss Exchange 11:20:01 2024-04-25 am EDT | ||
| 102.8 CHF | -0.48% |
|
| Current year | +1.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
Static data
| Product type | Obligations Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| RMACUV | |
| ISIN | CH1293293978 |
| Date issued | 2023-10-20 |
| Strike | 677.7 kr |
| Maturity | 2025-04-22 (336 Days) |
| Parity | 0.68 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | les deux |
| Currency | CHF |
Technical Indicators
| Highest since issue | 103.3 CHF |
|---|---|
| Lowest since issue | 99.4 CHF |
| Spread | 17 CHF |
| Spread % | 1.64% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
927.2
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.94%
- Stock Market
- Certificates
- RMACUV Certificat